| PPB | platelet-poor blood; pneumococcal pneumonia and bacteremia; positive pressure breathing |
|---|---|
| PPS | Personal Preference Scale; physician, patient and society [course]; polyvalent pneumococcal polysacc... |
| PPV | pneumococcal polysaccharide vaccine; porcine parvovirus; positive predictive value; positive pressur... |
| ACIP | acute canine idiopathic polyneuropathy; Advisory Committee on Immunization Practices [CDC] |
| DPI | daily permissible intake; days post inoculation; dietary protein intake; diphtheria-pertussis immuni... |
| CII | Childhood Immunization Initiative |
|---|---|
| EPI | Expanded Program of Immunization |
| NID | National Immunization Day |
| NIS | National Immunization Survey |
| PnC | Pneumococcal C polysaccharide |
| pneumococcal pneumonia immunization | This vaccine, which prevents one of the most common and severe forms of pneumonia, is usually given only once in a lifetime, usually after the age of 55, to someone with ongoing lung problems (such as chronic obstructive pulmonary disease or asthma) or other chronic diseases (including those involving the heart and kidneys). This vaccination would rarely be given to children. (12 Dec 1998) |
|---|---|
| immunization, pneumococcal pneumonia | This vaccine, which prevents one of the most common and severe forms of pneumonia, is usually given only once in a lifetime, usually after the age of 55, to someone with ongoing lung problems (such as chronic obstructive pulmonary disease (copd) or asthma) or other chronic diseases (including those involving the heart and kidneys). This vaccination would rarely be given to children. (12 Dec 1998) |
| meningitis, pneumococcal | Meningitis caused by bacteria of the species streptococcus pneumoniae. This condition can develop as a complication of pneumococcal pneumonia; by extension from otitis, mastoiditis, or sinusitis; following a skull injury; or without preceding sign of infection elsewhere. (12 Dec 1998) |
| pneumococcal | Pertaining to or containing the pneumococcus. (05 Mar 2000) |
| pneumococcal empyema | Infection of the pleural cavity by Streptococcus pneumoniae, the pneumococcus, with pus formation. Pulsating empyema, a large, tense collection of pus in the pleural cavity through which the cardiac pulsations are transmitted to the chest wall. Streptococcal empyema, purulent exudation into the pleural cavity caused by infection with Streptococcus haemolyticus. (05 Mar 2000) |
| pneumococcal infections | Infections with bacteria of the species streptococcus pneumoniae. (12 Dec 1998) |
| pneumococcal pneumonia | Pneumonia due to infection by Streptococcus pneumoniae; often of lobar distribution. (05 Mar 2000) |
| pneumococcal polysaccharide | A soluble type-specific polysaccharide produced during active growth of virulent pneumococci composing a large part of the capsule. Synonym: pneumococcal polysaccharide, soluble specific substance, specific soluble polysaccharide, specific soluble sugar. (05 Mar 2000) |
| pneumococcal/suppurative keratitis | A severe, creeping, central, suppurative ulcer often due to pneumococci. Synonym: pneumococcal/suppurative keratitis, serpent ulcer of cornea. (05 Mar 2000) |
| pneumococcal vaccine | Vaccine comprised of purified capsular polysaccharide antigen from 23 types of Streptococcus pneumoniae (representing those types responsible for most of the reported pneumococcal diseases in the U.S.). (05 Mar 2000) |
| pneumonia, pneumococcal | A febrile disease caused by streptococcus pneumoniae. This condition is characterised by inflammation of one or more lobes of the lungs and symptoms include chills, fever, rapid breathing, and cough. (12 Dec 1998) |
| active immunization | The production of active immunity. (05 Mar 2000) |
| anthrax immunization | A series of six shots over six months and booster shots annually, the anthrax vaccine now in use in the USA was first developed in the 1950s and approved by the Food and Drug Administration for general use in 1970. It is produced by the Michigan Biologic Products Institute of Michigan's Department of Health and is given routinely to veterinarians and others working with livestock. In December, 1997 it was announced that all US military would receive the vaccine, as do the military in the UK and Russia, the reason being concern that anthrax might be used in biologic warfare. (12 Dec 1998) |
| german measles immunization | The standard MMR vaccine is given to prevent measles, mumps and rubella (German measles). The MMR vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or MMR vaccination prior to entrance. Most children should receive MMR vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the MMR vaccine. Pregnant women should wait until after delivery before being immunised with MMR. People with HIV or AIDS should normally receive MMR vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination. (12 Dec 1998) |
| passive immunization | The production of passive immunity. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|